For an annual fee of £249, some companies now offer subscription-based blood testing services aimed at providing personalized health insights and lifestyle advice. These businesses promise to help users detect early signs of disease and optimize their well-being through regular monitoring of multiple biomarkers. However, experts question the overall benefit and potential risks of such widespread screening in asymptomatic individuals.
Among the prominent offerings is Do Health, founded by Dr. Rangan Chatterjee, which provides three blood tests per year conducted at clinics, with results delivered via an app. The service assesses more than 50 markers, including cholesterol, blood sugar, and organ function indicators. Customers receive a biological age score and tailored weekly plans that adjust based on their results. While Dr. Chatterjee, a public health advocate known for promoting lifestyle changes, contends that early measurement of key biomarkers could transform prevention of conditions such as type 2 diabetes and Alzheimer’s disease, his current professional status has come under scrutiny as he no longer holds a UK medical license.
Direct-to-consumer blood testing has attracted celebrity endorsements, with television personalities like Gabby Logan and Davina McCall promoting services like One Day Tests and Do Health, respectively. One Day Tests, for example, offers finger-prick kits and targets women with packages like “Ultimate Healthy Woman,” which examines 47 markers. Marketing messages often emphasize empowerment and the ability to “take control” of health, positioning these services as alternatives to traditional healthcare pathways.
However, public health specialists warn of the limitations and potential harms of screening individuals without symptoms. Dr. Angela Raffle, a consultant in public health, emphasizes that blood testing is complex and that many flagged abnormalities can be harmless variations rather than indicators of disease. She highlights the risk of overdiagnosis and unnecessary follow-up testing triggered by results falling outside standard reference ranges, which occur in approximately five percent of healthy individuals for any given marker. With panels measuring dozens of biomarkers, the likelihood of at least one abnormal finding among healthy people increases substantially, possibly leading to anxiety and unwarranted medical interventions.
Similarly, Professor Victoria Tzortziou Brown, president of the Royal College of General Practitioners, noted that additional testing without a clear clinical purpose and follow-up strategy does not inherently improve healthcare outcomes and may increase false-positive results.
Both Do Health and One Day Tests state that their services are designed as lifestyle and coaching programs rather than diagnostic tools. They stress that customers with concerning results are advised to consult with healthcare professionals. Do Health affirmed that each test result comes with clinical interpretation and personalized guidance, while One Day Tests said its results are carefully reviewed before recommending patients seek further medical evaluation.
The Advertising Standards Authority is currently investigating claims made by Do Health following a complaint, reflecting ongoing concerns about the advertising and regulation of these emerging services.
As interest in personal health monitoring grows, the medical community continues to weigh the promise of early detection against the risks of unnecessary testing, underlining the need for informed decision-making and clear communication about the benefits and limitations of blood testing subscriptions.